Comparability of Single Measurements of Serum Testosterone to the 24‐Hour Cavg in Patients Using Testosterone 2% Solution. (1st November 2014)
- Record Type:
- Journal Article
- Title:
- Comparability of Single Measurements of Serum Testosterone to the 24‐Hour Cavg in Patients Using Testosterone 2% Solution. (1st November 2014)
- Main Title:
- Comparability of Single Measurements of Serum Testosterone to the 24‐Hour Cavg in Patients Using Testosterone 2% Solution
- Authors:
- Muram, David
Baygani, Simin - Abstract:
- Abstract: Introduction: Efficacy of testosterone replacement therapy is determined by the proportion of men with 24‐hour average serum testosterone concentration (Cavg ) in the normal range. In clinical practice, monitoring and dose adjustments are based on single testosterone measurements; however, how single measurements reflect Cavg is unclear. Aim: This post‐hoc analysis evaluated whether single serum testosterone measurements and Cavg from the same day are both in the normal range in men receiving testosterone replacement therapy. Methods: In an open‐label, multicenter, titration trial, androgen‐deficient men (N = 155) were started on 60‐mg daily morning dose of testosterone 2% solution (Axiron®, Eli Lilly and Company, Indianapolis, Indiana, USA) applied to axillae (30 mg/axilla). Serum testosterone Cavg was determined on Days 15, 60, and 120. If necessary, dose was adjusted to maintain Cavg in the normal range (300–1, 050 ng/dL). This analysis included subjects (n = 105) whose Cavg was within the normal range on Days 15, 60, and 120. Main Outcome Measures: Proportion of men with normal serum testosterone levels at 2, 4, or 8 hours post‐dose on Days 15, 60, and 120. Results: Greater than 93% of subjects had testosterone serum levels within the normal range 2, 4, or 8 hours post‐dose on at least 1 day. In subjects with blood samples available from Days 15 and 60 or Days 15 and 120, 71.1% to 79.8% had normal levels at 2, 4, or 8 hours post‐dose on both days, and inAbstract: Introduction: Efficacy of testosterone replacement therapy is determined by the proportion of men with 24‐hour average serum testosterone concentration (Cavg ) in the normal range. In clinical practice, monitoring and dose adjustments are based on single testosterone measurements; however, how single measurements reflect Cavg is unclear. Aim: This post‐hoc analysis evaluated whether single serum testosterone measurements and Cavg from the same day are both in the normal range in men receiving testosterone replacement therapy. Methods: In an open‐label, multicenter, titration trial, androgen‐deficient men (N = 155) were started on 60‐mg daily morning dose of testosterone 2% solution (Axiron®, Eli Lilly and Company, Indianapolis, Indiana, USA) applied to axillae (30 mg/axilla). Serum testosterone Cavg was determined on Days 15, 60, and 120. If necessary, dose was adjusted to maintain Cavg in the normal range (300–1, 050 ng/dL). This analysis included subjects (n = 105) whose Cavg was within the normal range on Days 15, 60, and 120. Main Outcome Measures: Proportion of men with normal serum testosterone levels at 2, 4, or 8 hours post‐dose on Days 15, 60, and 120. Results: Greater than 93% of subjects had testosterone serum levels within the normal range 2, 4, or 8 hours post‐dose on at least 1 day. In subjects with blood samples available from Days 15 and 60 or Days 15 and 120, 71.1% to 79.8% had normal levels at 2, 4, or 8 hours post‐dose on both days, and in subjects with blood samples available from Days 15, 60, and 120, 63.9% to 68.8% had normal levels at 2, 4, or 8 hours post‐application on all 3 days. Conclusion: Less than 70% of single testosterone measurements made on 3 separate days were concordant with same‐day Cavg for all 3 days. These findings, which are specific for testosterone 2% solution, indicate that single measurements do not always reflect the 24‐hour Cavg, and may possibly lead to inappropriate dose adjustments. … (more)
- Is Part Of:
- Journal of sexual medicine. Volume 11:Number 11(2014:Nov.)
- Journal:
- Journal of sexual medicine
- Issue:
- Volume 11:Number 11(2014:Nov.)
- Issue Display:
- Volume 11, Issue 11 (2014)
- Year:
- 2014
- Volume:
- 11
- Issue:
- 11
- Issue Sort Value:
- 2014-0011-0011-0000
- Page Start:
- 2826
- Page End:
- 2829
- Publication Date:
- 2014-11-01
- Subjects:
- Testosterone -- Testosterone 2% Solution -- Hypogonadism -- Axiron -- Testosterone Deficiency Syndrome
Sexual disorders -- Periodicals
Sex -- Periodicals
Sexual health -- Periodicals
616.69005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1743-6109 ↗
http://www.blackwell-synergy.com/openurl?genre=journal&eissn=1743-6109 ↗
http://www.blackwell-synergy.com/servlet/useragent?func=showIssues&code=jsm ↗
https://academic.oup.com/jsm ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/jsm.12656 ↗
- Languages:
- English
- ISSNs:
- 1743-6095
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5064.060000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26335.xml